ILMN - Illumina, Inc.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Biondo Investment Advisors LLC bought a new stake in shares of Illumina, Inc. (NASDAQ: ILMN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,630 shares of the life sciences company's stock, valued at approximately $1,869,000. Several other institutional investors and
Allworth Financial LP acquired a new position in Illumina, Inc. (NASDAQ: ILMN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,976 shares of the life sciences company's stock, valued at approximately $1,051,000. Several other hedge funds and other institutional investors have
Illumina delivered strong Q2 2026 results, beating on EPS and revenue, and raised full-year guidance for both metrics. ILMN's profitability and momentum are robust, with management emphasizing margin expansion, ongoing share buybacks, and significant cash flow. Despite a D- valuation and stagnant historical revenue, Wall Street analysts are revising growth estimates upward, anticipating a revenue breakout by 2027.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Empowered Funds LLC raised its stake in Illumina, Inc. (NASDAQ: ILMN) by 104.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,996 shares of the life sciences company's stock after purchasing an additional 6,633 shares during the period. Empowered
Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript
Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago.
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth") GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31 "Illumina delivered strong results during the second quarter.
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in “Hallucinating Value: Healthcare's AI Narrative.” The findings come from the Fishbone Health.
Amova Asset Management Americas Inc. trimmed its position in Illumina, Inc. (NASDAQ: ILMN) by 18.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 721,532 shares of the life sciences company's stock after selling 165,333 shares during the period. Illumina comprises 1.3% of Amova
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.